BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
43 hedge funds and large institutions have $8.85M invested in BRAINSTORM CELL THERAPUTC in 2019 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
10% more funds holding
Funds holding: 39 → 43 (+4)
7% more capital invested
Capital invested by funds: $8.24M → $8.85M (+$609K)
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
0.02% less ownership
Funds ownership: 0.63% → 0.61% (-0.02%)
82% less call options, than puts
Call options by funds: $244K | Put options by funds: $1.38M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$142K |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$135K |
| 3 |
BlackRock
New York
|
+$120K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$47.3K |
| 5 |
CG
CFO4Life Group
Coppell,
Texas
|
+$46.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
-$315K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$128K |
| 3 |
CPP
Crow Point Partners
Boston,
Massachusetts
|
-$104K |
| 4 |
VF
Virtu Financial
New York
|
-$51K |
| 5 |
WG
Winton Group
London,
United Kingdom
|
-$46.2K |
BCLI Hedge Fund Activity: Q4 2019 in Review
43 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q4 2019, worth a combined $8.85M — up 7.4% from $8.24M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BCLI positions and 3 closed out — a net gain of 4 holders — while 10 added to existing stakes and 10 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $142K. The largest seller was Group One Trading, cutting an estimated $315K.
- 43 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q4 2019, up from 39 in Q3 2019.
- Funds reported $8.85M of BRAINSTORM CELL THERAPUTC stock for Q4 2019, up 7.4% quarter-over-quarter.
- 7 funds opened new BRAINSTORM CELL THERAPUTC positions in Q4 2019 and 3 closed out, a net change of +4 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q4 2019 was Renaissance Technologies, an estimated $142K added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q4 2019 was Group One Trading, an estimated $315K sold.
Based on aggregated 13F filings for Q4 2019.